Upload File

sirona biochem fact sheet jan.2016

1
Company Overview Recent News • SBM Reaches Major Milestone with Successful Scale-up of Skin Lightening Compound SBM-TFC-1067 • SBM Announces Positive Results of SBM-TFC-837 Anti-aging Regenerative and Regenerative Medicine • SBM Completes Exclusive Licensing Agreement with Leading Anti-Diabetic Company in China, Wanbang Biopharmaceuticals • SBM Completes Global Exclusive Licensing Agreement with Obagi Medical Products / Valeant Pharmaceuticals • SBM Announces Joint Venture with Bloom Burton & Co. • Proprietary platform technology • Strong IP portfolio • Risk diversified business model • Early stage technology licensing • Generating revenue • Award-winning • EU and French Government grants Stock Information TSX-V: SBM Frankfurt/Xetra®: ZSB As of January 2016 • Market Cap: $25.5M • Outstanding Shares: 154M Contact Information Proprietary Platform Technology Stabilizing carbohydrates for improved safety and efficacy Management Team Dr. Howard Verrico, CEO Dr. Geraldine Deliencourt-Godefroy, CSO Christopher Hopton, CFO Attila Hajdu, CBDO Michelle Seltenrich, VP Operations Sirona Biochem cautions you that statements included in this profile that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements. Pharmaceutical Pipeline SGLT2 Inhibitor Anti-Inflammatory Anti-Infective Anti-Aging Cosmetic Pipeline ADVANCING CHEMISTRY ENHANCING HEALTH Pre-clinical Chemistry / Patent Testing & Validation Market Skin Lightening Chemistry / Patent Stage of Development Product Stage of Development Product Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem (located in France) is the recipient of multiple French scientific awards and European Union and French government grants. twitter.com/sironabiochem Value Proposition Stage Available for Licensing Market Pre-revenue In Revenue Pre-revenue In Revenue linkedin.com/company/sirona- biochem-corp. facebook.com/pages/Sirona- Biochem-Corp/110521942342739 Social Media Ph I Ph II Ph III Licensing Status Stage Available for Licensing Clinical Licensing Status Sirona Biochem Corp Head Office 605 - 889 West Pender Street Vancouver, BC, V6C 3B2 Tel : 604.641.4466 Toll Free : 1.888.747.6621 [email protected] www.sironabiochem.com TFChemistry Laboratory - Cosmetic Valley Voie de l’innovation Pharma Parc II Chaussée du Vexin 27100 Val de Reuil France Tel :+33(0)2.32.09.01.16 Fax :+33(0)2.32.25.07.64 www.tfchemistry.com SGLT2 Inhibitor (China) (ROW)* *ROW - Rest of World -TFC-849 -TFC-723 -TFC-1067

Upload: momentumpr

Post on 12-Jan-2017

242 views

Category:

Investor Relations


3 download

Report

TRANSCRIPT

Page 1: Sirona Biochem Fact Sheet jan.2016

Company Overview

Recent News • SBMReachesMajorMilestonewithSuccessfulScale-upofSkinLighteningCompoundSBM-TFC-1067

• SBMAnnouncesPositiveResultsofSBM-TFC-837Anti-agingRegenerativeandRegenerativeMedicine

• SBMCompletesExclusiveLicensingAgreementwithLeadingAnti-DiabeticCompanyinChina,WanbangBiopharmaceuticals

• SBMCompletesGlobalExclusiveLicensingAgreementwithObagiMedicalProducts/ValeantPharmaceuticals

• SBMAnnouncesJointVenturewithBloomBurton&Co.

• Proprietaryplatformtechnology• StrongIPportfolio• Riskdiversifiedbusinessmodel• Earlystagetechnologylicensing• Generatingrevenue• Award-winning• EUandFrenchGovernmentgrants

Stock InformationTSX-V:SBMFrankfurt/Xetra®:ZSB As of January 2016

• MarketCap:$25.5M• OutstandingShares:154M

Contact Information

Proprietary Platform TechnologyStabilizing carbohydrates for improved safety and efficacy

Management TeamDr.HowardVerrico,CEODr.GeraldineDeliencourt-Godefroy,CSOChristopherHopton,CFOAttilaHajdu,CBDOMichelleSeltenrich,VPOperations

SironaBiochemcautionsyouthatstatementsincludedinthisprofilethatarenotadescriptionofhistoricalfactsmaybeforward-lookingstatements.Forward-lookingstatementsareonlypredictionsbaseduponcurrentexpectationsandinvolveknownandunknownrisksanduncertainties.Youarecautionednottoplaceunduerelianceontheseforward-lookingstatements,whichspeakonlyasofthedateofreleaseoftherelevantinformation,unlessexplicitlystatedotherwise.Actualresults,performanceorachievementcoulddiffermateriallyfromthoseexpressedin,orimpliedby,SironaBiochem’sforward-lookingstatementsduetotherisksanduncertaintiesinherentinSironaBiochem’sbusinessincluding,withoutlimitation,statementsabout:theprogressandtimingofitsclinicaltrials;difficultiesordelaysindevelopment,testing,obtainingregulatoryapproval,producingandmarketingitsproducts;unexpectedadversesideeffectsorinadequatetherapeuticefficacyofitsproductsthatcoulddelayorpreventproductdevelopmentorcommercialization;thescopeandvalidityofpatentprotectionforitsproducts;competitionfromotherpharmaceuticalorbiotechnologycompanies;anditsabilitytoobtainadditionalfinancingtosupportitsoperations.SironaBiochemdoesnotassumeanyobligationtoupdateanyforward-lookingstatements.

Pharmaceutical Pipeline

SGLT2 Inhibitor

Anti-Inflammatory

Anti-Infective

Anti-Aging

Cosmetic Pipeline

ADVANCING CHEMISTRYENHANCING HEALTH

Pre-clinical

Chemistry / Patent Testing & Validation MarketSkin Lightening

Chemistry / Patent

Stage of DevelopmentProduct

Stage of DevelopmentProduct

Sirona Biochem is a cosmetic ingredient and drug discoverycompanywithaproprietaryplatformtechnology.Sironaspecializesin stabilizing carbohydratemoleculeswith the goal of improvingefficacy and safety.New compounds are patented formaximumrevenuepotential.

Sirona’s compounds are licensed to leading companies aroundtheworldinreturnforlicensingfees,milestonefeesandongoingroyaltypayments.Sirona’slaboratory,TFChem(locatedinFrance)istherecipientofmultipleFrenchscientificawardsandEuropeanUnionandFrenchgovernmentgrants.

twitter.com/sironabiochem

Value Proposition

StageAvailableforLicensing

Market

Pre-revenue

InRevenue

Pre-revenue

InRevenue

linkedin.com/company/sirona-biochem-corp.

facebook.com/pages/Sirona-Biochem-Corp/110521942342739

Social Media

Ph I Ph II Ph III

LicensingStatus

StageAvailableforLicensing

Clinical

LicensingStatus

Sirona Biochem CorpHeadOffice605-889WestPenderStreetVancouver,BC,V6C3B2Tel:604.641.4466TollFree:[email protected]

TFChemistry Laboratory-CosmeticValleyVoiedel’innovationPharmaParcIIChausséeduVexin27100ValdeReuilFranceTel:+33(0)2.32.09.01.16Fax:+33(0)2.32.25.07.64www.tfchemistry.com

SGLT2 Inhibitor

(China)

(ROW)*

*ROW-RestofWorld

-TFC-849-TFC-723-TFC-1067

SBM Investor Presentation June 2019 - Sirona Biochem Corp. · Rodan + Fields. The compound, which was tested in a clinical trial in the USA, was shown to be better than 2% Hydroquinone

Cybex Sirona

Sirona Biochem Si - cash.ch · 2015-01-12  · 12 January 2015 B Sirona Biochem Page 3/33 INVESTMENT CASE Innovative, multifaceted technology Carbohydrate molecules are vital to countless

RINN Product Catalog - Dentsply Sirona USA · dürr, hdX, mediadent, progeny mps/mpse, gendexVisualiX/gX-s sirona Not for Sirona XIOS or XIOS Plus 551150 sirona Complete Kit 4 Arms

Sertifikat Sirona 3

Sirona Biochem Investor Presentation · 2021. 6. 1. · Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may

Biochem 11

sirona 1 (1)

Biochem (Siegel)

Biochem Nutrition

Lab Biochem

Biochemistry & Ariyurek et al., Biochem Anal Biochem … · Biochem Anal Biochem ISSN:2161-1009 Biochem, an open access journal . Keywords: ... turbidimetry and nephelometry in each

Fallstudie | Sirona

The BIOCHEM project - Plastice · BIOCHEM Project . BIOCHEM ... WP 1 Project Management 13 BIOCHEM Accelerator BIOCHEM ToolBox ... o Opportunity assessment questionnaire

Biochem Ppt

SIRONA – WELTWEIT EINMALIGE SYSTEMKOMPETENZ FÜR … The Dental Company The Dental Company DAS SIRONA-ERGONOMIE-PROGRAMM Wir sorgen für Entspannung. Sirona Dental Systems · Fabrikstraße

Surveyor - Dentsply Sirona

Investor Presentation - Sirona Biochem...TFC-039, exclusively in the People’s Republic of China (PRC) • In return for the license, Wanbang provides upfront and milestone payments

Sertifikat Sirona 4

Biochem 5ed

Proteins biochem

Biochem textbook

Sirona Biochem Corporate Presentation

Dentsply Sirona

CYBEX Sirona handleiding

Детские автокресла Cybex Sirona Black River (514105008), · Детские автокресла Cybex Sirona Black River (514105008), Sirona Ocean (514105009), Sirona

Biochem Introduction

Biochem Carbohydrates

Biochem 2010

Virtual Emerging Biotech - Sirona Biochem

Cerec Sirona

Sirona Biochem Investor Presentation

DE EN IT FR NL PL SIRONA Z i-SIZE | SIRONA S i-SIZE ... · CYBEX Sirona Z i-Size CYBEX Sirona S i-Size CYBEX Sirona M2 i-Size. 5 DE EN IT Thank you very much for purchasing a SENSORSAFE

Biochem basics

Biochem mutations